TCRT · Alaunos Therapeutics, Inc.
AI read · Bad for TCRT
The AI's read
Those programs might add value, but the filing gives no details about them. The preferred shares could become about 138 million common shares after a shareholder vote. A Velaris director and the lead investor's picks could then hold 4 of 5 board seats. The possible share increase and shift in control outweigh the program opportunity whose value is not stated.